QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
Log in
ASX:SUD

Suda Pharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.04
MA: A$0.04
A$0.04
52-Week Range N/A
Volume842,145 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Suda Pharmaceuticals Ltd operates as a drug delivery company that focuses on oro-mucosal administration in Australia. Its product pipeline includes ZolpiMist, a US approved, oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia; ArTiMist, a sub-lingual spray for the treatment of p. falciparum severe paediatric malaria; SUD-001, an oral spray formulation that is used for the treatment of acute migraine in adults; and SUD-002, an oral spray formulation of ondansetron to treat nausea and vomiting induced by chemotherapy or radiotherapy, and other post-operative settings. Its product pipeline also comprises SUD-003, an oral spray formulation of sildenafil sprayed directly in the mouth over the tongue for the treatment of erectile dysfunction; SUD-004, an oral spray formulation of sildenafil to treat pulmonary arterial hypertension in adults; and SUD-005, an oral spray formulation of midazolam for the treatment of pre-procedure anxiety in imaging and dental procedures, and also in the treatment of epileptic seizures. In addition, it distributes medical devices, pharmaceuticals, vaccines, and consumables to hospitals, aged care facilities, pharmacies, mining companies, and other healthcare providers. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH for ZolpiMist oral spray. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd is based in Osborne Park, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 8 6142 5555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.25 million
Book ValueA$0.03 per share

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive SUD News and Ratings via Email

Sign-up to receive the latest news and ratings for SUD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Suda Pharmaceuticals (ASX:SUD) Frequently Asked Questions

Who are some of Suda Pharmaceuticals' key competitors?

Who are Suda Pharmaceuticals' key executives?

Suda Pharmaceuticals' management team includes the following people:
  • Mr. Stephen Carter, CEO & MD
  • Mr. Joseph Daniel Ohayon, CFO & Company Sec.
  • Dr. Carol Worth, Chief Technical Officer

What is Suda Pharmaceuticals' stock symbol?

Suda Pharmaceuticals trades on the ASX under the ticker symbol "SUD."

How big of a company is Suda Pharmaceuticals?

Suda Pharmaceuticals has a market capitalization of $0.00 and generates $1.25 million in revenue each year.

What is Suda Pharmaceuticals' official website?

The official website for Suda Pharmaceuticals is sudapharma.com.

How can I contact Suda Pharmaceuticals?

The company can be reached via phone at 61 8 6142 5555.

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.